- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04677452
Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
An Open-Label Phase 1 Dose Exploration Study of JWCAR129, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Jiangsu
-
Suzhou, Jiangsu, Kina, 215000
- Rekrytering
- First Affiliated Hospital, SooChow University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18 years old and above.
- Signed the Informed Consent Form.
Diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Subjects must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen). Subjects must be refractory to the last anti-myeloma treatment regimen prior to entering the study.
- Autologous hematopoietic stem cell transplantation.
- A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination. Subjects must have undergone at least 2 consecutive cycles of treatment for each regimen unless progressive disease was the best response to the regimen.
- Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy.
Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible; the reason for not receiving treatment must be clearly documented in the case report form.
- Subjects must have measurable disease.
- Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function
Exclusion Criteria:
- Subjects with known active or history of CNS involvement by malignancy
- Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis
- History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.
- Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])
- Prior CAR T-cell or other genetically-modified T-cell therapy
- Prior treatment with a BCMA-targeted agent
- History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
- Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JWCAR129 infusion.
- History of any of the following cardiovascular conditions within 6 months of initial screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease
- History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study
- Allogeneic hematopoietic stem cell transplantation.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: JWCAR129
Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
|
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129.
During JWCAR129 production, participants may receive bridging chemotherapy for disease control.
Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of dose-limiting toxicities (DLTs)
Tidsram: 28 days
|
Proportion of subjects with adverse events meeting DLT criteria
|
28 days
|
Incidence and severity of adverse events
Tidsram: 2 years
|
Proportion of subjects with adverse events overall and by severity grade
|
2 years
|
Incidence and severity of clinically significant laboratory abnormalities
Tidsram: 2 years
|
Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade
|
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cmax
Tidsram: 2 years
|
Maximum concentration (Cmax) of JWCAR129 in the blood
|
2 years
|
Tmax
Tidsram: 2 years
|
Time to maximum concentration (Tmax) of JWCAR129 in the blood
|
2 years
|
AUC
Tidsram: 2 years
|
Area under the concentration vs time curve (AUC) of JWCAR129 in the blood
|
2 years
|
Duration of persistence
Tidsram: 2 years
|
Duration of persistence of JWCAR129 CAR T cells in the blood
|
2 years
|
Overall response rate
Tidsram: 2 years
|
Proportion of subjects with a partial response (PR) or better by IMWG criteria
|
2 years
|
CR rate
Tidsram: 2 years
|
Proportion of subjects with a CR by IMWG criteria
|
2 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- JWCAR129
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Säkerhet och effektivitet
-
Assiut UniversityRekryteringSafety of Excision den nya tumörstorlekenEgypten
-
Tampere University HospitalTampere UniversityAvslutadFöräldratillfredsställelse | Föräldraskap Self-efficacyFinland
-
Fernanda Muñoz SepúlvedaSubvención Presidencial, Ministerio de Hacienda, Chile; Centro Interuniversitario... och andra samarbetspartnersAvslutadMunhälsa Kunskap | Munhälsa attityder | Munhälsa Self-efficacyChile
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RekryteringFallskada | Falls | Träna själveffektivitet | Falls Self-EfficacyFörenta staterna
-
AstraZenecaAvslutadMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)Ryska Federationen
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvslutadiPS Cell Manufacturing and Banking
-
Istituto Clinico HumanitasAvslutadGnRH Trigger and Rescue Protocol
-
Igdir UniversityRekrytering
-
Hacettepe UniversityAvslutadRädsla för förlossning | Leveranssätt | Motiverande intervju | Förlossning Self-efficacyKalkon
-
Inonu UniversityAvslutadUtbildning | Mobila meddelanden | Amning Self-efficacy | Amningsinställning | Tillfredsställelse av moderns upplevelseKalkon